ClinicalTrials.gg
RecruitingNCT06833476STRONGUpdated Sep 29, 2026

TTVR STRONG Under Coverage With Evidence Development (CED) Study

An observational study in Tricuspid Regurgitation, sponsored by Edwards Lifesciences. Recruiting at 1 site in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Edwards Lifesciences · Observational

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
2,044
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Tricuspid Valve Insufficiency by Edwards Lifesciences — 3 open to participants now, 10 under way, none of them phase 3. Tricuspid Valve Insufficiency · Edwards Lifesciences.

Started
2025
the only one that year
Observational
5 of 14
3 open now
Registered
13th of 14
by date

Among the 14 studies in Tricuspid Valve Insufficiency by Edwards Lifesciences, this one is the only one that started in 2025, is one of 5 observational ones, and was the 13th registered.

Tricuspid Valve Insufficiency

229 studies on the registry are indexed under Tricuspid Valve Insufficiency; 111 are open to participants now.

Browse Tricuspid Valve Insufficiency studies →

Open to participants now

3 of the 14 studies in Tricuspid Valve Insufficiency by Edwards Lifesciences are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 81 Tricuspid Valve Insufficiency studies recruiting now, 67 (83%) set no upper age limit and none (0%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Tricuspid Valve Insufficiency by Edwards Lifesciences, or all of them as a file.
02

Study summary

This Coverage with Evidence Development (CED) study measures the long-term health outcomes of patients with severe, symptomatic Tricuspid Regurgitation who received a Transcatheter Tricuspid Valve Replacement procedure using the EVOQUE system.

Read the detailed description

This is a retrospective, non-randomized cohort study measuring 2-year effectiveness of the EVOQUE Transcatheter Tricuspid Valve Replacement (TTVR) system in the real-world.

This study will retrospectively evaluate EVOQUE treated patients in the STS/ACC TVT Registry who have at least severe Tricuspid Regurgitation and can be deterministically linked with Medicare data.

This group will be compared to Medicare eligible and EVOQUE eligible patients evaluated in a standard of care setting from a commercial claims database linked with electronic health records.

We will evaluate the primary outcome measure in various subgroups.

There will be continued access enrollment after the primary completion date.

03

Conditions studied

  • Tricuspid Regurgitation

Keywords

  • EVOQUE
  • Coverage with Evidence Development
  • CED
  • TVT Registry
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Medicare eligible real-world patients with severe, symptomatic tricuspid regurgitation

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Medicare eligible patients who have received an EVOQUE device or are EVOQUE eligible and have at least severe Tricuspid Regurgitation

Exclusion criteria

Exclusion Criteria:

Commercially insured patients who have received an EVOQUE device or are EVOQUE eligible or Medicare eligible patients with less than severe Tricuspid Regurgitation

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
2,044 participants (estimated)
Patient registry
No

Groups and cohorts

  • EVOQUE treated

    Medicare patients with at least severe Tricuspid Regurgitation who received a Transcatheter Tricuspid Valve Replacement with the EVOQUE device and is identified in the TVT Registry

    Other: EVOQUE

  • EVOQUE eligible

    Medicare eligible patients with severe, symptomatic Tricuspid Regurgitation that are identifiable in a commercial claims database linked with electronic health records.

Interventions

  • OtherEVOQUE

    This is a retrospective, non-randomized study. The decision to intervene by TTVR with the EVOQUE device is made by the heart team.

06

What researchers measure

Primary outcomes

  1. Composite (All-Cause Death or Heart Failure Hospitalization)

    Time to death or heart failure hospitalization after time zero

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Dec 2027, 33 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2025
First posted
Feb 18, 2025
StartActual
Mar 19, 2025
Primary completionEst.
Dec 30, 2027
CompletionEst.
Dec 31, 2032
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: index terms and verification date
1 update, last Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Minor edits only
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06833476
Responsible party
Sponsor
First posted
Feb 18, 2025
Start date
Mar 19, 2025
Primary completion
Dec 30, 2027 (estimated)
Completion
Dec 31, 2032 (estimated)
Last update
Sep 29, 2026

Study contacts

TMTT GHER
Contact
TMTT_GHER_EVIDENCE@edwards.com
949-250-3849

Oversight

FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion